Comment

. 2023 Mar;113(3):471-472.

doi: 10.1002/cpt.2772. Epub 2022 Nov 22.

Plasma Uracil as a DPD Phenotyping Test: Pre-Analytical Handling Matters!

Fabienne Thomas¹, Manon Launay², Jérôme Guitton³, Marie-Anne Loriot^{4

5}, Jean-Christophe Boyer⁶, Vincent Haufroid⁷, Marie-Christine Etienne-Grimaldi⁸, Bernard Royer^{9

10}; GPCO-UNICANCER Group

Affiliations

¹ Centre de Recherches en Cancérologie, Inserm, CNRS, Université Toulouse III-Paul Sabatier and IUCT-Oncopole, Toulouse, France.
² Plateau de Biologie, CHU Saint Etienne, Saint Etienne, France.
³ Laboratoire de Pharmacologie Toxicologie, CHU de Lyon, Lyon, France.
⁴ Department of Clinical Chemistry, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.
⁵ INSERM UMRS1138, Centre de Recherche des Cordeliers, Université de Paris, Paris, France.
⁶ Biochemistry Laboratory, Carrémeau University Hospital, Nîmes, France.
⁷ Department of Clinical Chemistry, Cliniques Universitaires Saint-Luc and Louvain Centre for Toxicology and Applied Pharmacology (LTAP), Institut de Recherche Expérimentale et Clinique, UCLouvain, Brussels, Belgium.
⁸ Oncopharmacology Laboratory, Centre Antoine Lacassagne, Nice, France.
⁹ Laboratoire de Pharmacologie Clinique et Toxicologie, CHU Besançon, Besançon, France.
¹⁰ INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, University of Bourgogne Franche-Comté, Besançon, France.

PMID: 36412238
DOI: 10.1002/cpt.2772

Comment

Plasma Uracil as a DPD Phenotyping Test: Pre-Analytical Handling Matters!

Fabienne Thomas et al. Clin Pharmacol Ther. 2023 Mar.

. 2023 Mar;113(3):471-472.

doi: 10.1002/cpt.2772. Epub 2022 Nov 22.

Authors

Affiliations

¹ Centre de Recherches en Cancérologie, Inserm, CNRS, Université Toulouse III-Paul Sabatier and IUCT-Oncopole, Toulouse, France.
² Plateau de Biologie, CHU Saint Etienne, Saint Etienne, France.
³ Laboratoire de Pharmacologie Toxicologie, CHU de Lyon, Lyon, France.
⁴ Department of Clinical Chemistry, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.
⁵ INSERM UMRS1138, Centre de Recherche des Cordeliers, Université de Paris, Paris, France.
⁶ Biochemistry Laboratory, Carrémeau University Hospital, Nîmes, France.
⁷ Department of Clinical Chemistry, Cliniques Universitaires Saint-Luc and Louvain Centre for Toxicology and Applied Pharmacology (LTAP), Institut de Recherche Expérimentale et Clinique, UCLouvain, Brussels, Belgium.
⁸ Oncopharmacology Laboratory, Centre Antoine Lacassagne, Nice, France.
⁹ Laboratoire de Pharmacologie Clinique et Toxicologie, CHU Besançon, Besançon, France.
¹⁰ INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, University of Bourgogne Franche-Comté, Besançon, France.

PMID: 36412238
DOI: 10.1002/cpt.2772

No abstract available

PubMed Disclaimer

Comment in

Response to "Plasma Uracil as a DPD Phenotyping Test: Pre-analytical Handling Matters".
de With M, Knikman J, Schellens JHM, Gelderblom H, Cats A, Guchelaar HJ, Mathijssen RHJ, Swen JJ, Meulendijks D. de With M, et al. Clin Pharmacol Ther. 2023 Mar;113(3):473-475. doi: 10.1002/cpt.2775. Epub 2022 Nov 9. Clin Pharmacol Ther. 2023. PMID: 36352517 No abstract available.

Comment on

Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study.
de With M, Knikman J, de Man FM, Lunenburg CATC, Henricks LM, van Kuilenburg ABP, Maring JG, van Staveren MC, de Vries N, Rosing H, Beijnen JH, Pluim D, Modak A, Imholz ALT, van Schaik RHN, Schellens JHM, Gelderblom H, Cats A, Guchelaar HJ, Mathijssen RHJ, Swen JJ, Meulendijks D. de With M, et al. Clin Pharmacol Ther. 2022 Jul;112(1):62-68. doi: 10.1002/cpt.2608. Epub 2022 May 4. Clin Pharmacol Ther. 2022. PMID: 35397172 Free PMC article.

Cited by

Case report: 5-Fluorouracil treatment in patient with an important partial DPD deficiency.
Schmitt A, Royer B, Boidot R, Berthier J, Ghiringhelli F. Schmitt A, et al. Front Oncol. 2023 Jun 20;13:1187052. doi: 10.3389/fonc.2023.1187052. eCollection 2023. Front Oncol. 2023. PMID: 37409256 Free PMC article.
A Guide for Implementing DPYD Genotyping for Systemic Fluoropyrimidines into Clinical Practice.
Ho TT, Smith DM, Aquilante CL, Cicali EJ, El Rouby N, Hertz DL, Imanirad I, Patel JN, Scott SA, Swain SM, Tuteja S, Hicks JK; Pharmacogenomics Global Research Network Publication Committee. Ho TT, et al. Clin Pharmacol Ther. 2025 May;117(5):1194-1208. doi: 10.1002/cpt.3567. Epub 2025 Jan 31. Clin Pharmacol Ther. 2025. PMID: 39887719 Free PMC article. Review.
Case report: A case of severe capecitabine toxicity due to confirmed in trans compound heterozygosity of a common and rare DPYD variant.
de Haar-Holleman A, Cortoos PJ, Vlaeminck J, Van Landuyt P, Steurbaut S, Vaeyens F, Haufroid V. de Haar-Holleman A, et al. Front Pharmacol. 2024 Sep 23;15:1459565. doi: 10.3389/fphar.2024.1459565. eCollection 2024. Front Pharmacol. 2024. PMID: 39376610 Free PMC article.

References

1. de With, M. et al. Dihydropyrimidine dehydrogenase phenotyping using pretreatment uracil: a note of caution based on a large prospective clinical study. Clin. Pharmacol. Ther. 112, 62-68 (2022).
1. Maillard, M. et al. Quantitative impact of pre-analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency. Br. J. Clin. Pharmacol. (2022). https://doi.org/10.1111/bcp.15536. [e-pub ahead of print].
1. Jacobs, B.A.W. et al. Development and validation of a rapid and sensitive UPLC-MS/MS method for determination of uracil and dihydrouracil in human plasma. J. Pharm. Biomed. Anal. 126, 75-82 (2016).
1. Capiau, S., Van Landschoot, A., Reyns, T. & Stepman, H. Pre-analytical considerations for the analysis of uracil and 5,6-dihydrouracil in heparin plasma. Clin. Chem. Lab. Med. 60, e112-e115 (2022).
1. Recommandations et référentiels, INCa, HAS, décembre 2018. Recherche d'’un déficit en dihydropyrimidine deshydrogénase visant à prévenir certaines toxicités sévères associées aux traitements par fluoropyrimidines. <https://www.has-sante.fr/portail/upload/docs/application/pdf/2018-12/rec....

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Plasma Uracil as a DPD Phenotyping Test: Pre-Analytical Handling Matters!

Affiliations

Plasma Uracil as a DPD Phenotyping Test: Pre-Analytical Handling Matters!

Authors

Affiliations

Comment in

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Comment in

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources